Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 15/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 13/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4350703 | 0.87 | OPRM1 (0.48) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL4344641 | 0.86 | OPRM1 (0.56) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL4352452 | 0.85 | OPRL1 (0.49) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL4344823 | 0.85 | OPRM1 (0.59) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL4352252 | 0.83 | OPRM1 (0.46) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL4347994 | 0.82 | OPRM1 (0.46) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL3410347 | 0.81 | OPRM1 (0.48) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL3405713 | 0.80 | CHRM1 (0.51) | OPRL1OPRM1 | |
| SCHEMBL4425740 | 0.80 | CHRM1 (0.51) | OPRL1OPRM1 | |
| SCHEMBL4341728 | 0.79 | OPRM1 (0.43) | OPRL1OPRM1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275574-A1 | NOVEL COMPOUNDS-300 | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | claimed |
| US-20090275574-A1 | NOVEL COMPOUNDS-300 | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20090275574-A1 | NOVEL COMPOUNDS-300 | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275574-A1 | NOVEL COMPOUNDS-300 | CACNA1A, SCN10A, OPRM1 | OPRL1 4/4885OPRM1 3/4885OPRK1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.